Cinven Takes Majority Stake in Medpace for $915 Million

Private-equity firm Cinven Ltd. agreed to buy a majority stake in Medpace Inc., which helps pharmaceutical companies manage research and clinical trials, from CCMP Capital Advisors LLC for $915 million.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.